Vertex Pharmaceuticals Incorporated v. Aurobindo Pharma Limited et al
| Vertex Pharmaceuticals Incorporated |
| Aurobindo Pharma Limited and Aurobindo Pharma U.S.A., Inc. |
| 1:2022cv00728 |
| June 3, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Christopher J Burke |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 29, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 18
SO ORDERED Granting Proposed Order to Consolidate and Amend Scheduling Order filed (*Reset Deadlines: Amended Pleadings due by 1/6/2023, Fact Discovery completed by 3/31/2023, Joinder of Parties due by 1/6/2023, a 3 day Bench Trial is set to start 2/20/2024, at 8:30 AM in Courtroom 6A, a Pretrial Conference is set for 2/9/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 7/29/2022. Associated Cases: 1:20-cv-00988-RGA-CJB, 1:22-cv-00728-RGA(nms)
|
| CASE REFERRED to Magistrate Judge Christopher J. Burke. (nms) |
| Filing 17 PROPOSED ORDER to Consolidate and Amend Scheduling Order, by Vertex Pharmaceuticals Incorporated. (Fahnestock, Derek) Modified on 7/28/2022 (nms). |
| Filing 16 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding Proposed Consolidated Scheduling Order. (Fahnestock, Derek) |
| Filing 15 NOTICE OF SERVICE of Initial Disclosures Under Paragraph 4(c) of the District of Delaware Default Standard for Discovery filed by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) |
| Filing 14 NOTICE OF SERVICE of Production of Defendants' Core Technical Documents Pursuant to Paragraph 4(b) of the Delaware Default Standard for Discovery and Pursuant to the Standing Order Regarding Hatch-Waxman Cases in Which Infringement is Alleged filed by Aurobindo Pharma Limited, Aurobindo Pharma U.S.A., Inc..(Myer, R.) |
| Pro Hac Vice Attorney Timothy H. Kratz and Michael P. Hogan for Aurobindo Pharma Limited and Aurobindo Pharma U.S.A., Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 13 MOTION for Pro Hac Vice Appearance of Attorney Michael P. Hogan - filed by Aurobindo Pharma Limited, Aurobindo Pharma U.S.A., Inc.. (Myer, R.) |
| Filing 12 MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz - filed by Aurobindo Pharma Limited, Aurobindo Pharma U.S.A., Inc.. (Myer, R.) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma U.S.A., Inc. filed by Aurobindo Pharma Limited, Aurobindo Pharma U.S.A., Inc.. (Myer, R.) |
| Filing 10 ANSWER to #1 Complaint, by Aurobindo Pharma Limited, Aurobindo Pharma U.S.A., Inc..(Myer, R.) |
|
SO ORDERED, re #12 MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz, filed by Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited, and #13 MOTION for Pro Hac Vice Appearance of Attorney Michael P. Hogan, filed by Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited. Signed by Judge Richard G. Andrews on 6/27/2022. (nms)
|
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 9 AFFIDAVIT of Service for Summons, Complaint and Related Papers served on Aurobindo Pharma Limited on June 6, 2022, filed by Vertex Pharmaceuticals Incorporated. (Fahnestock, Derek) |
| Filing 8 SUMMONS Returned Executed by Vertex Pharmaceuticals Incorporated. Aurobindo Pharma U.S.A., Inc. served on 6/6/2022, answer due 6/27/2022. (Blumenfeld, Jack) |
| Filing 7 Summons Issued as to Aurobindo Pharma Limited on 6/2/2022. (srs) |
| Filing 6 Summons Issued as to Aurobindo Pharma U.S.A., Inc. on 6/2/2022. (srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Vertex Pharmaceuticals Incorporated. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,646,481 B2. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 21, 2022. Date of Expiration of Patent: August 13, 2029.Thirty Month Stay Deadline: October 21, 2024. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT filed against Aurobindo Pharma Limited and Aurobindo Pharma U.S.A., Inc. ( Filing fee $ 402, receipt number ADEDC-3887797.) - filed by Vertex Pharmaceuticals Incorporated. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(srs) (Additional attachment(s) added on 6/6/2022: #1 Exhibit A, #2 Civil Cover Sheet) (smg). |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
